PerkinElmer, Inc.

719 articles with PerkinElmer, Inc.

• PerkinElmer Adds HPLC Columns to Consumables Portfolio

  3/8/2021

  PerkinElmer, Inc ., a global leader committed to innovating for a healthier world, today announced that it has added state-of-the-art columns and chemistries to its LC consumables portfolio by acquiring ES Industries , based in West Berlin, New Jersey in the U.S.

• PerkinElmer Prices Offering of Senior Notes - Mar 05, 2021

  3/5/2021

  PerkinElmer, Inc., a global leader committed to innovating for a healthier world, announced that it has priced an offering of $400.0 million aggregate principal amount of 2.550% Senior Notes due 2031 at an issue price of 99.965% of the principal amount and $400.0 million aggregate principal amount of 3.625% Senior Notes due 2051 at an issue price of 99.999% of the principal amount.

• PerkinElmer Changes COVID-19 Rapid Testing Landscape with Highly Sensitive Point of Care Antigen Test for Mass Screening

  2/23/2021

  Company expands portfolio of SARS-CoV-2 testing solutions with rapid antigen test benchmarked against gold standard RT-PCR

• PerkinElmer Provides an Update on Valencia Branch Laboratory’s Accreditation Process

  2/22/2021

  PerkinElmer, Inc., (NYSE: PKI) a global leader committed to innovating for a healthier world, today provided an update on the COVID-19 Valencia Branch Laboratory’s (VBL) accreditation process.

• PerkinElmer Launches First Cell Painting Kit

  2/16/2021

  New PhenoVue™ cell painting reagent kit makes the process of “painting” cells easier for research scientists by providing carefully selected and pre-optimized reagents

• PerkinElmer to Present at Cowen Health Care Conference

  2/16/2021

  PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the 41 st Annual Cowen Health Care Conference on Monday, March 1, 2021 from 12:20 p.m. to 12:50 p.m. ET.

• PerkinElmer Announces Financial Results for the Fourth Quarter and Full Year of 2020

  2/2/2021

  4Q Revenue of $1.355 billion; 68% reported growth; 65% organic growth 4Q GAAP EPS from continuing operations of $3.38; Adjusted EPS of $3.96 Initiates First Quarter and Full Year 2021 Guidance

• PerkinElmer Board Declares Quarterly Dividend - Jan 28, 2021

  1/28/2021

  The Board of Directors of PerkinElmer, Inc., declared a regular quarterly dividend of $0.07 per share of common stock January 28, 2021.

• PerkinElmer Launches Industry-First GPCR TR-FRET Binding Assay and Beta-Arrestin Kits to Help Advance Therapeutics Discovery

  1/26/2021

  New offerings join PerkinElmer’s leading GPCR Portfolio across characterization and screening assays, screening libraries and workflow optimization

• PerkinElmer SARS-CoV-2 RT-PCR Assay Receives FDA EUA for Asymptomatic Testing

  1/14/2021

  PerkinElmer, Inc. (NYSE:PKI) announced today that its PerkinElmer ® New Coronavirus Nucleic Acid Detection Kit received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) to test individuals without symptoms or other reasons to suspect COVID-19 infection. According to a new model f

• EUROIMMUN Launches SARS-CoV-2 Test System to Detect T-Cell Response

  1/14/2021

  Novel test supports vaccine development studies critical to aiding researchers in understanding immunity levels and disease progression

• PerkinElmer Updates Fourth Quarter Outlook; To Hold Earnings Call on Tuesday, February 2, 2021

  1/11/2021

  PerkinElmer, Inc., a global leader committed to innovating for a healthier world, announced that it anticipates reported and organic revenue growth of approximately 66% and 63%, respectively, GAAP earnings per share from continuing operations of at least $2.88, and adjusted earnings per share from continuing operations of at least $3.60 for the fourth quarter ended January 3, 2021.

• PerkinElmer to Present at J.P. Morgan Healthcare Conference - Dec 16, 2020

  12/16/2020

  PerkinElmer, Inc., a global leader committed to innovating for a healthier world, announced that the Company will present at the annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 7:30 a.m. ET.

• Charnwood Lighthouse Lab Goes Live Processing Thousands of COVID-19 Tests per Day with PerkinElmer Solutions

  11/30/2020

  UK’s newest Lighthouse Lab boosts the country’s COVID-19 testing capacity, while generating hundreds of new local jobs

• PerkinElmer to Host Virtual Life Science Event

  11/17/2020

  PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will host a Virtual Life Science Event for the investment community on Thursday, December 10 at 8:30 a.m. ET. This event is organized to serve as an in-depth breakdown of the Company’s business serving Life Science End Markets, including its portfolio, strategy, latest innovations and scien

• PerkinElmer Launches New HPLC, UHPLC and Next Generation Software Solution

  11/16/2020

  LC 300™ platform and SimplicityChrom™ software offers improved workflows, intuitive user interface and 21 CFR Part 11 compliance

• PerkinElmer Brings ChemDraw Software to the Cloud, Enhancing Search and Collaboration Workflows

  11/10/2020

  PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today launched its newest ChemDraw® application, ChemOffice®+ Cloud, to simplify, facilitate and accelerate chemistry communication workflows. The ChemDraw platform is the leading chemistr

• EUROIMMUN Launches Quantitative ELISA to Measure SARS-CoV-2 Antibodies Against Viral S1 Protein

  11/9/2020

  PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, announced today that EUROIMMUN, a PerkinElmer company, has launched the Anti-SARS-CoV-2 QuantiVacTM ELISA (IgG) to quantify IgG antibodies against the SARS-CoV-2 S1 antigen.

• PerkinElmer to Present at Wolfe Virtual Healthcare Conference

  11/5/2020

  PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the Wolfe Virtual Healthcare Conference on Thursday, November 19 at 11:25 a.m. ET.

• PerkinElmer to Present at Stifel Virtual Healthcare Conference

  11/4/2020

  PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the Stifel Virtual Healthcare Conference on Tuesday, November 17, 2020 at 1:20 p.m. ET. Jamey Mock, SVP and chief financial officer of PerkinElmer, will provide an update on the Company and its strategic prioriti